{
    "Code": "AZN",
    "Type": "Common Stock",
    "Name": "AstraZeneca PLC",
    "Exchange": "LSE",
    "CurrencyCode": "GBX",
    "CurrencyName": "Pence sterling",
    "CurrencySymbol": "p",
    "CountryName": "UK",
    "CountryISO": "GB",
    "OpenFigi": null,
    "ExchangeMarket": "LSE - MAIN MARKET",
    "ISIN": "GB0009895292",
    "LEI": "PY6ZZQWO2IZFZC3IOL08",
    "PrimaryTicker": "AZN.LSE",
    "CIK": null,
    "EmployerIdNumber": "",
    "FiscalYearEnd": "December",
    "IPODate": "1993-05-12",
    "InternationalDomestic": "International/Domestic",
    "Sector": "Healthcare",
    "Industry": "Drug Manufacturers - General",
    "GicSector": "Health Care",
    "GicGroup": "Pharmaceuticals, Biotechnology & Life Sciences",
    "GicIndustry": "Pharmaceuticals",
    "GicSubIndustry": "Pharmaceuticals",
    "Description": "AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. It has a strategic agreement with Tempus to develop the largest multimodal foundation model in oncology. The company has a collaboration agreement with IonQ, Inc. for the development of quantum-accelerated computational chemistry workflow for healthcare, life sciences, and chemistry; a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications; and collaboration Revna Biosciences for lung cancer treatment. AstraZeneca PLC was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.",
    "Address": "1 Francis Crick Avenue, Cambridge, United Kingdom, CB2 0AA",
    "AddressData": {
        "Street": "1 Francis Crick Avenue",
        "City": "Cambridge",
        "Country": "United Kingdom",
        "ZIP": "CB2 0AA"
    },
    "Listings": {
        "0": {
            "Code": "AZN",
            "Exchange": "US",
            "Name": "AstraZeneca PLC ADR"
        }
    },
    "Officers": {
        "0": {
            "Name": "Mr. Pascal Claude Roland Soriot D.V.M., M.B.A.",
            "Title": "CEO & Executive Director",
            "YearBorn": "1959"
        },
        "1": {
            "Name": "Dr. Aradhana  Sarin M.D.",
            "Title": "CFO & Executive Director",
            "YearBorn": "1974"
        },
        "2": {
            "Name": "Ms. Pam P. Cheng",
            "Title": "EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board",
            "YearBorn": "1970"
        },
        "3": {
            "Name": "Mr. Andrew P. Barnett",
            "Title": "Head of Investor Relations",
            "YearBorn": "NA"
        },
        "4": {
            "Name": "Mr. Jeffrey  Pott J.D.",
            "Title": "CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board",
            "YearBorn": "NA"
        },
        "5": {
            "Name": "Dr. Ruud  Dobber Ph.D.",
            "Title": "Executive Vice-President of BioPharmaceuticals Business Unit",
            "YearBorn": "NA"
        },
        "6": {
            "Name": "Dr. Susan Mary Galbraith M.D., Ph.D.",
            "Title": "Executive Vice President of Oncology R&D",
            "YearBorn": "1966"
        },
        "7": {
            "Name": "Ms. Iskra  Reic",
            "Title": "Executive Vice President of International",
            "YearBorn": "NA"
        },
        "8": {
            "Name": "Mr. David  Fredrickson",
            "Title": "Executive Vice-President of Oncology Haematology Business Unit",
            "YearBorn": "1975"
        },
        "9": {
            "Name": "Ms. Ruth  March",
            "Title": "Senior VP of Precision Medicine - R&D Oncology",
            "YearBorn": "NA"
        }
    },
    "Phone": "44 20 3749 5000",
    "WebURL": "https://www.astrazeneca.com",
    "LogoURL": "/img/logos/LSE/azn.png",
    "FullTimeEmployees": 94300,
    "UpdatedAt": "2025-09-14"
}